Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,701–3,800 of 10,906
Sernicola, A., Dybała, A., Gomes, V., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17807 · Cited by 18
Coppeta, L., Balbi, O., Grattagliano, Z., Mina, G. G., Pietroiusti, A., Magrini, A., Bolcato, M., & Aurilio, M. T. (2021) · Vaccines · doi:10.3390/vaccines9060659 · Cited by 21
Matsuda, M., Asanuma, Y., Yokota, K., Sakai, S., Yazawa, H., Maruyama, T., Wada, T. T., Araki, Y., & Mimura, T. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0590-22 · Cited by 22
Nahass, G. R., Salomon, R. E. A., Blacker, G., Haider, K., Brotherton, R., Teague, K., Yiu, Y. Y., Brewer, R. E., Galloway, S., Hansen, P. S., et al. (2021) · medRxiv · doi:10.1101/2021.08.22.21262168 · Cited by 22
Vijayan, A., Vogels, R., Groppo, R., Jin, Y., Khan, S., van Kampen, M., Jorritsma, S. H. T., Boedhoe, S., Baert, M. R. M., van Diepen, H. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54289-9 · Cited by 22
Non-viral mRNA delivery to the lungs
Healy, L., Seto, B. Y., Cui, H., & Li, B. (2025) · Biomaterials Science · doi:10.1039/d5bm00322a · Cited by 25
Nucleic Acid Vaccines against SARS-CoV-2
Liu, Y., & Ye, Q. (2022) · Vaccines · doi:10.3390/vaccines10111849 · Cited by 18
McConnell, S. A., Sachithanandham, J., Mudrak, N. J., Zhu, X., Farhang, P. A., Cordero, R. J. B., Wear, M. P., Shapiro, J. R., Park, H.-S., Klein, S. L., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.011 · Cited by 20
COVID-19 and Type 1 Diabetes: Addressing Concerns and Maintaining Control
DiMeglio, L. A. (2021) · Diabetes Care · doi:10.2337/dci21-0002 · Cited by 22
Humbert, M. V., Opurum, P. C., Brendish, N. J., Poole, S., He, P., Katis, I. N., Quaye, J., Bediako, Y., Duriez, P. J., Eason, R. W., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.08.049 · Cited by 17
Rovida, F., Cassaniti, I., Percivalle, E., Sarasini, A., Paolucci, S., Klersy, C., Cutti, S., Novelli, V., Marena, C., Luzzaro, F., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.07.003 · Cited by 17
Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses
Huayamares, S. G., Lian, L., Rab, R., Hou, Y., Radmand, A., Kim, H., Zenhausern, R., Achyut, B. R., Gilbert‐Ross, M., Lokugamage, M. P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58548-1 · Cited by 19
Gu, J., Xu, Z., Liu, Q., Tang, S., Zhang, W., Xie, S., Chen, X., Chen, J., Yong, K., Yang, C., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202302409 · Cited by 21
Ousseine, Y. M., Vaux, S., Vandentorren, S., Bonmarin, I., Champenois, K., Lydié, N., & Velter, A. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095372 · Cited by 17
Gooch, K. E., Smith, T. R. F., Salguero, F. J., Fotheringham, S. A., Watson, R. J., Dennis, M. J., Handley, A., Humphries, H. E., Longet, S., Tipton, T., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.057 · Cited by 20
T-Cell Immune Responses to SARS-CoV-2 Infection and Vaccination
Notarbartolo, S. (2024) · Vaccines · doi:10.3390/vaccines12101126 · Cited by 23
Inhalable polymer nanoparticles for versatile mRNA delivery and mucosal vaccinationPreprint
Suberi, A., Grun, M. K., Mao, T., Israelow, B., Reschke, M., Grundler, J., Akhtar, L., Lee, T., Shin, K., Piotrowski-Daspit, A. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.22.485401 · Cited by 18
Corrao, G., Franchi, M., Cereda, D., Bortolan, F., Leoni, O., Vignati, E., Pavesi, G., & Gori, A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07823-3 · Cited by 19
Corbisier, P., Petrillo, M., Marchini, A., Querci, M., Buttinger, G., Bekliz, M., Spieß, K., Polacek, C., Fomsgaard, A., & den Eede, G. V. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105191 · Cited by 17
Population-Wide Persistent Hemostatic Changes After Vaccination With ChAdOx1-S
de Laat, B., Stragier, H., Kremers, R., Ninivaggi, M., Mesotten, D., Thiessen, S., Pelt, K. V., Roest, M., Penders, J., Vanelderen, P., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.966028 · Cited by 18
Animal vaccine revolution: Nanoparticle adjuvants open the future of vaccinology
Xu, S., Sun, C., Qian, T., Chen, Y., Dong, X., Wang, A., Zhang, Q., Ji, Y., Jin, Z., Liu, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113827 · Cited by 19
Applications of multiplexed CRISPR–Cas for genome engineering
Cheng, H., Jeong, E., & Cho, S. W. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01500-6 · Cited by 30
Timing the race of vaccination, new variants, and relaxing restrictions during COVID-19 pandemic
Xavier, C. R., Oliveira, R. S., Vieira, V. D. F., Rocha, B. M., Reis, R. F., Quintela, B. D. M., Lobosco, M., & dos Santos, R. W. (2022) · Journal of Computational Science · doi:10.1016/j.jocs.2022.101660 · Cited by 22
COVID-19 Vaccines: Where Did We Stand at the End of 2023?
Lundstrom, K. H. (2024) · Viruses · doi:10.3390/v16020203 · Cited by 27
Exploring the possible link between myocarditis and mRNA COVID-19 vaccines
Sinagra, G., Merlo, M., & Porcari, A. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.08.018 · Cited by 17
(2021) · doi:10.1101/2021.06.01.21258172 · Cited by 425
Effects of human mobility and behavior on disease transmission in a COVID-19 mathematical model
Gutiérrez-Jara, J. P., Vogt-Geisse, K., Cabrera, M., Córdova‐Lepe, F., & Muñoz-Quezada, M. T. (2022) · Scientific Reports · doi:10.1038/s41598-022-14155-4 · Cited by 24
Polymeric Carriers for Delivery of RNA Cancer Therapeutics
Mirón‐Barroso, S., Correia, J. S., Frampton, A. E., Lythgoe, M. P., Clark, J., Tookman, L. A., Ottaviani, S., Castellano, L., Porter, A. E., Georgiou, T. K., et al. (2022) · Non-Coding RNA · doi:10.3390/ncrna8040058 · Cited by 19
Bişgin, A., Şanlioğlu, A. D., Ekşi, Y. E., Griffith, T. S., & Şanlıoğlu, S. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.052 · Cited by 19
Pépin, J., Labbé, A., Carignan, A., Parent, M., Yu, J. W., Grenier, C., Beauchemin, S., Wals, P. D., Valiquette, L., & Rousseau, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.019 · Cited by 19
Ballout, A. A., Babaie, A., Kolesnik, M., Li, J. Y., Hameed, N., Waldman, G., Chaudhry, F., Saba, S., Harel, A., & Najjar, S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.796882 · Cited by 17
Eid, J., Abdelwahab, M., Williams, H., Caplan, M., Hajmurad, S., Venkatesh, K. K., Costantine, M. M., & Rood, K. M. (2022) · American Journal of Reproductive Immunology · doi:10.1111/aji.13596 · Cited by 19
Nakamura, K., Fujimoto, K., Hasegawa, C., Aoki, I., Yoshitsugu, H., Ugai, H., Yatsuzuka, N., Tanaka, Y., Furihata, K., Maas, B. M., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13395 · Cited by 21
Shao, Y., Wu, Y., Feng, Y., Xu, W., Xiong, F., & Zhang, X. (2022) · Frontiers of Medicine · doi:10.1007/s11684-021-0913-y · Cited by 23
Strategies to Overcome Hurdles in Cancer Immunotherapy
Kim, J. H., Lee, B. J., Moon, S., Lee, H., Lee, J., Kim, B., Jung, K., Seo, H., & Chung, Y. (2024) · Biomaterials Research · doi:10.34133/bmr.0080 · Cited by 21
Newly diagnosed IgA nephropathy with gross haematuria following COVID-19 vaccination
Horino, T., Sawamura, D., Inotani, S., Ishihara, M., Komori, M., & Ichii, O. (2021) · QJM · doi:10.1093/qjmed/hcab305 · Cited by 18
Dembiński, Ł., Martins, M. V., Huss, G., Grossman, Z., Barak, S., Magendie, C., del Torso, S., Dornbusch, H. J., Mazur, A., Albrecht, K., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.721257 · Cited by 18
Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
Anichini, G., Terrosi, C., Savellini, G. G., Gandolfo, C., Franchi, F., & Cusi, M. G. (2021) · Vaccines · doi:10.3390/vaccines9050517 · Cited by 19
Meggiolaro, A., Schepisi, M. S., Nikolaidis, G., Mipatrini, D., Siddu, A., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10020157 · Cited by 21
A community-partnered approach for diversity in COVID-19 vaccine clinical trials
Castellon‐Lopez, Y., Landovitz, R. J., Ntekume, E., Porter, C. L., Bross, R., Hilder, R., Lucas‐Wright, A., Daar, E. S., Chavez, P. I., Blades, C., et al. (2022) · Journal of Clinical and Translational Science · doi:10.1017/cts.2022.471 · Cited by 24
Rota, M., Torresan, I., Palmerio, S., Tasselli, E., Rossi, A., Zivi, A., & Zacchi, F. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105068 · Cited by 27
Lipid nanoparticles as a tool to dissect dendritic cell maturation pathways
Rennen, S., Bosteels, V., Nolf, C. D., Maréchal, S., Vetters, J., Lil, K. V., Webb, G. R., Swinnen, J., Velde, E. V. D., Fayazpour, F., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116150 · Cited by 23
McGrath, J., McAloon, C. G., More, S. J., Garrett, S., Reidy, C., Geary, Ú., Noonan, N., & Bergin, C. J. (2022) · Epidemiology and Infection · doi:10.1017/s0950268822001595 · Cited by 17
Coronavirus disease 2019 vaccination in transplant recipients
Eberhardt, C. S., Balletto, E., Cornberg, M., & Mikulska, M. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000739 · Cited by 19
A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18
Yousef, M., Rob, M., Varghese, S., Rao, S., Zamir, F., Paul, P., & Châari, A. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122535 · Cited by 23
Kanizsai, A., Molnár, T., Várnai, R., Závori, L., Tökés‐Füzesi, M., Szalai, Z., Berecz, J., & Csécsei, P. (2022) · Vaccines · doi:10.3390/vaccines10030447 · Cited by 20
Kassardjian, A., Sun, E., Sookhoo, J. R. V., Muthuraman, K., Boligan, K. F., Kucharska, I., Rujas, E., Jetha, A., Branch, D. R., Babiuk, S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112391 · Cited by 18
Nanotechnology-Enabled COVID-19 mRNA Vaccines
Gao, Y., Yang, K., Shelling, A. N., & Wu, Z. (2021) · Encyclopedia · doi:10.3390/encyclopedia1030059 · Cited by 20
Flitter, B. A., Braun, M. R., & Tucker, S. N. (2022) · Vaccines · doi:10.3390/vaccines10040593 · Cited by 20
Development of Therapeutic RNA Manipulation for Muscular Dystrophy
Saifullah, S., Motohashi, N., Tsukahara, T., & Aoki, Y. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.863651 · Cited by 22
A reasoned approach towards administering COVID‐19 vaccines to pregnant women
Pramanick, A., Kanneganti, A., Wong, J. L. J., Li, S. W., Dimri, P. S., Mahyuddin, A. P., Kumar, S., Illanes, S. E., Chan, J. K. Y., Su, L., et al. (2021) · Prenatal Diagnosis · doi:10.1002/pd.5985 · Cited by 20
Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
Hatzakis, A. E., Karabinis, A., Roussos, S., Pantazis, N., Degiannis, D., Chaidaroglou, A. S., Petsios, K. T., Pavlopoulou, I. D., Tsiodras, S., Paraskevis, D. N., et al. (2022) · Vaccines · doi:10.3390/vaccines10020285 · Cited by 18
Amanzio, M., Cipriani, G. E., & Bartoli, M. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1900728 · Cited by 19
Tedeschi, S. K., Ellrodt, J., Stratton, J., Santacroce, L. M., Chandler, P. D., Gravallese, E. M., & Solomon, D. H. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11351 · Cited by 16
Runnstrom, M. C., Lamothe, P. A., Faliti, C. E., Cheedarla, N., Moreno, A., Suthar, M. S., Nahata, R., Ravindran, M., Haddad, N. S., Morrison-Porter, A., et al. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.03.029 · Cited by 18
Nurses’ mental health from early COVID‐19 pandemic to vaccination
Kim, S. C., Rankin, L., & Ferguson, J. (2021) · Journal of Nursing Scholarship · doi:10.1111/jnu.12760 · Cited by 20
COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective
Cavaillon, J.-M., & Osuchowski, M. F. (2021) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2021.04.003 · Cited by 17
“[95] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al.”
Lyophilized SARS-CoV-2 self-amplifying RNA vaccines for microneedle array patch delivery
Driskill, M. M., Coates, I. A., Hurst, P. J., Rajesh, N. U., Dulay, M. T., Waymouth, R. M., Akahata, W., Matsuda, K., Smith, J., Jacobson, G. B., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113944 · Cited by 23
Salter, S. M., Li, D., Trentino, K. M., Nissen, L. M., Lee, K., Orlemann, K., Peters, I., Murray, K., Leeb, A., & Deng, L. (2022) · Vaccines · doi:10.3390/vaccines10122017 · Cited by 15
Yang, H. J., Hong, W., Shi, H., He, C., Hong, L., Zhou, Y., Yang, H., Alu, A., Chen, Z., Yang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-55087-z · Cited by 18
Comparative characteristics of COVID-19 vaccines used for mass immunisation
Онищенко, Г. Г., Sizikova, T. E., Lebedev, V. N., & Borisevich, S. V. (2021) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2021-21-3-158-166 · Cited by 21
Branching in poly(amine-co-ester) polyplexes impacts mRNA transfection
Shin, K., Suh, H., Suberi, A., Whang, C., Ene, M., Grundler, J., Grun, M. K., & Saltzman, W. M. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122692 · Cited by 16
Jiang, M., Väisänen, E., Kolehmainen, P., Huttunen, M., Ylä‐Herttuala, S., Meri, S., Österlund, P., & Julkunen, I. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.04.049 · Cited by 24
Transverse myelitis 48 hours after the administration of an mRNA COVID 19 vaccine
McLean, P., & Trefts, L. (2021) · Neuroimmunology Reports · doi:10.1016/j.nerep.2021.100019 · Cited by 17
Kremsner, P. G., Guerrero, R. A. A., Arana, E., Aroca Martinez, G. J., Bonten, M. J. M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2021) · doi:10.2139/ssrn.3911826 · Cited by 17
Lin, Y., Liao, X., Cao, X., Zhang, Z., Wang, X., He, X., Liao, H., Ju, B., Qi, F., Xu, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci175233 · Cited by 23
“Currently, viral vaccines, including inactivated, adenovirus-packaged, and mRNA formulations, are predominantly administered via intra-muscular (IM) injection to stimulate systemic antiviral immunity (2–5).”
AMDV Vaccine: Challenges and Perspectives
Markarian, N. M., & Abrahamyan, L. G. (2021) · Viruses · doi:10.3390/v13091833 · Cited by 18
Dynamics of SARS-CoV-2 Major Genetic Lineages in Moscow in the Context of Vaccine Prophylaxis
Gushchin, V. А., Pochtovyi, A. A., Kustova, D. D., Ogarkova, D. A., Tarnovetskii, I. Y., Belyaeva, E. D., Divisenko, E. V., Vasilchenko, L. A., Shidlovskaya, E. V., Kuznetsova, N. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314670 · Cited by 17
Switzer, B., Haanen, J. B. A. G., Lorigan, P. C., Puzanov, I. J., & Turajlic, S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002835 · Cited by 17
Pandemic Preparedness Against Influenza: DNA Vaccine for Rapid Relief
Andersen, T. K., Bodin, J., Oftung, F., Bogen, B., Mjaaland, S., & Grødeland, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.747032 · Cited by 18
Ruiz, P. L., Gunnes, N., Gran, J. M., Karlstad, Ø., Selmer, R. M., Dahl, J., Bøås, H., White, R. A., Hofman, A. C., Paulsen, T. H., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.085 · Cited by 20
Design Rules for the Nano‐Bio Interface of Nanodiamonds: Implications for siRNA Vectorization
Kindermann, M., Neburková, J., Neuhöferová, E., Majer, J., Stejfova, M., Benson, V., & Cígler, P. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202314088 · Cited by 17
Kacherovsky, N. A., Yang, L. F., Dang, H. V., Cheng, E. L., Cardle, I. I., Walls, A. C., McCallum, M., Sellers, D. L., DiMaio, F., Salipante, S. J., et al. (2021) · Angewandte Chemie · doi:10.1002/ange.202107730 · Cited by 20
Platelet and immune signature associated with a rapid response to the BNT162b2 mRNA COVID‐19 vaccine
Flego, D., Cesaroni, S., Romiti, G. F., Corica, B., Marrapodi, R., Scafa, N., Maiorca, F., Lombardi, L., Pallucci, D., Pulcinelli, F. M., et al. (2022) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15648 · Cited by 18
Rouphael, N., & Bausch-Jurken, M. T. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad162 · Cited by 18
Self-citationGong, S. Y., Ding, S., Benlarbi, M., Chen, Y., Vézina, D., Marchitto, L., Beaudoin-Bussières, G., Goyette, G., Bourassa, C., Bo, Y., et al. (2022) · Viruses · doi:10.3390/v14102178 · Cited by 20
Qassim, S. H., Hasan, M. R., Tang, P., Chemaitelly, H. S., Ayoub, H. H., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Rahim, H. F. A., Nasrallah, G. K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.984784 · Cited by 20
mRNA Vaccines: Current Applications and Future Directions
Li, J., Liu, Y., Dai, J., Li, Y., Xiong, F., Xia, J., Jin, J., Wu, Y., & Peng, X. (2025) · MedComm · doi:10.1002/mco2.70434 · Cited by 40
Naseem‐Khan, S., Berger, M. B., Leddin, E. M., Maghsoud, Y., & Cisneros, G. A. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00201 · Cited by 18
Luo, J., Zhang, Z., Song, Z., & Gao, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076369 · Cited by 23
Li, X., Wichai, N., Wang, J., Liu, X., Yan, H., Wang, Y., Luo, M., Zhou, S., Wang, K., Lin, L., et al. (2022) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000046 · Cited by 18
Loosen, S. H., Bohlken, J., Weber, K., Konrad, M., Luedde, T., Roderburg, C., & Kostev, K. (2022) · Vaccines · doi:10.3390/vaccines10040566 · Cited by 16
Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy
Kim, H. J., Seo, S. K., & Park, H. Y. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.029 · Cited by 19
Vaccines Against COVID-19: A Review
Torres-Estrella, C. U., Reyes-Montes, M. D. R., Duarte-Escalante, E., Sierra-Martínez, M., León, M. G. F.-D., & Acosta‐Altamirano, G. (2022) · Vaccines · doi:10.3390/vaccines10030414 · Cited by 19
Richardson, J. R., Götz, R., Mayr, V., Lohse, M. J., Holthoff, H., & Ungerer, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266701 · Cited by 16
Meggiolaro, A., Sane Schepisi, M., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., & Rezza, G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2130773 · Cited by 17
Fryer, H. A., Hartley, G. E., Edwards, E. S. J., Varese, N. P., Boo, I., Bornheimer, S. J., Hogarth, P. M., Drummer, H. E., O’Hehir, R. E., & van Zelm, M. C. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01527-2 · Cited by 14
Brunelli, S. M., Sibbel, S., Karpinski, S., Marlowe, G., Walker, A. G., Giullian, J., Wyck, D. V., Kelley, T., Lazar, R., Zywno, M. L., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021101395 · Cited by 18
Nanomedicine-based strategies for the treatment of vein graft disease
Zhou, Z., Chen, W., Cao, Y., Abdi, R., & Tao, W. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01094-y · Cited by 21
Course and Lethality of SARS-CoV-2 Epidemic in Nursing Homes after Vaccination in Florence, Italy
Rivasi, G., Bulgaresi, M., Mossello, E., et al. (2021) · Vaccines · doi:10.3390/vaccines9101174 · Cited by 17
Scalable multimodal weak anion exchange chromatographic purification for stable mRNA drug substance
Megušar, P., Miklavčič, R., Korenč, M., Ličen, J., Seravalli, T. V., Černigoj, U., Štrancar, A., & Sekirnik, R. (2023) · Electrophoresis · doi:10.1002/elps.202300106 · Cited by 20
Corrao, G., Franchi, M., Cereda, D., Bortolan, F., Zoli, A., Leoni, O., Borriello, C., Valle, G. P. D., Tirani, M., Pavesi, G., et al. (2022) · Lancet. Infectious Diseases (Print) · doi:10.1016/s1473-3099(21)00813-6 · Cited by 17
Gauci, M.-L., Coutzac, C., Houot, R., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.02.003 · Cited by 17
Braun, E., Horowitz, N. A., Leiba, R., Weissman, A., Mekel, M., Shachor‐Meyouhas, Y., Hussein, K., Halberthal, M., Azzam, Z. S., & Berger, G. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.07.002 · Cited by 16
Sood, A., Tran, M., Murthy, V., & González, E. B. (2022) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001871 · Cited by 22
The syndrome of inappropriate antidiuresis after vaccination against COVID-19: case report
Lindner, G., & Ryser, B. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06690-8 · Cited by 19
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.